These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21497936)

  • 21. Targeting mRNA splicing as a potential treatment for Duchenne muscular dystrophy.
    Kole R; Leppert BJ
    Discov Med; 2012 Jul; 14(74):59-69. PubMed ID: 22846203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical, biochemical, and molecular studies in pyridoxine-dependent epilepsy. Antisense therapy as possible new therapeutic option.
    Pérez B; Gutiérrez-Solana LG; Verdú A; Merinero B; Yuste-Checa P; Ruiz-Sala P; Calvo R; Jalan A; Marín LL; Campos O; Ruiz MÁ; San Miguel M; Vázquez M; Castro M; Ferrer I; Navarrete R; Desviat LR; Lapunzina P; Ugarte M; Pérez-Cerdá C
    Epilepsia; 2013 Feb; 54(2):239-48. PubMed ID: 23350806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of pre-mRNA splicing by antisense oligonucleotides.
    Kole R
    Acta Biochim Pol; 1997; 44(2):231-7. PubMed ID: 9360712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The therapeutic potential of antisense-mediated exon skipping.
    van Ommen GJ; van Deutekom J; Aartsma-Rus A
    Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineering U7snRNA gene to reframe transcripts.
    Goyenvalle A
    Methods Mol Biol; 2012; 867():259-71. PubMed ID: 22454067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Present and future of antisense therapy for splicing modulation in inherited metabolic disease.
    Pérez B; Rodríguez-Pascau L; Vilageliu L; Grinberg D; Ugarte M; Desviat LR
    J Inherit Metab Dis; 2010 Aug; 33(4):397-403. PubMed ID: 20577904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antisense genes to induce exon inclusion.
    Nlend RN; Schümperli D
    Methods Mol Biol; 2012; 867():325-47. PubMed ID: 22454071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA mis-splicing in disease.
    Scotti MM; Swanson MS
    Nat Rev Genet; 2016 Jan; 17(1):19-32. PubMed ID: 26593421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies.
    Li D; McIntosh CS; Mastaglia FL; Wilton SD; Aung-Htut MT
    Transl Neurodegener; 2021 May; 10(1):16. PubMed ID: 34016162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease.
    El Marabti E; Abdel-Wahab O
    Trends Mol Med; 2021 Jul; 27(7):643-659. PubMed ID: 33994320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mRNA trans-splicing in gene therapy for genetic diseases.
    Berger A; Maire S; Gaillard MC; Sahel JA; Hantraye P; Bemelmans AP
    Wiley Interdiscip Rev RNA; 2016 Jul; 7(4):487-98. PubMed ID: 27018401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of aberrant splicing in human RNA diseases by chemical compounds.
    Kataoka N
    Hum Genet; 2017 Sep; 136(9):1237-1245. PubMed ID: 28364159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antisense oligonucleotides and other genetic therapies made simple.
    Rossor AM; Reilly MM; Sleigh JN
    Pract Neurol; 2018 Apr; 18(2):126-131. PubMed ID: 29455156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA-based therapies for genodermatoses.
    Bornert O; Peking P; Bremer J; Koller U; van den Akker PC; Aartsma-Rus A; Pasmooij AM; Murauer EM; Nyström A
    Exp Dermatol; 2017 Jan; 26(1):3-10. PubMed ID: 27376675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of alternative splicing with chemical compounds in new therapeutics for human diseases.
    Ohe K; Hagiwara M
    ACS Chem Biol; 2015 Apr; 10(4):914-24. PubMed ID: 25560473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inherited Retinal Disease Therapies Targeting Precursor Messenger Ribonucleic Acid.
    Huang D; Fletcher S; Wilton SD; Palmer N; McLenachan S; Mackey DA; Chen FK
    Vision (Basel); 2017 Sep; 1(3):. PubMed ID: 31740647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Splicing modulation therapy in the treatment of genetic diseases.
    Arechavala-Gomeza V; Khoo B; Aartsma-Rus A
    Appl Clin Genet; 2014; 7():245-52. PubMed ID: 25506237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense DNAs as targeted genetic medicine to treat cancer.
    Cho-Chung YS
    Arch Pharm Res; 2003 Mar; 26(3):183-91. PubMed ID: 12723929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.
    Pagliarini V; La Rosa P; Sette C
    Hum Genet; 2017 Sep; 136(9):1215-1235. PubMed ID: 28434044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.